特瓦制药公司宣布FDA批准WELTRUZA™用于精神分裂症的每月注射型奥兰扎平

Teva Pharmaceuticals has received FDA approval for WELTRUZA™, a once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for treating schizophrenia in adults, marking the first of its kind with no loading doses, oral supplementation, or post-injection monitoring required.

为什么重要. 精神分裂症患者现在有了一个新的、更便捷的治疗选择，这可能会提高依从性并改善长期症状管理。